Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine.
about
Serological study of vaccinia virus reservoirs in areas with and without official reports of outbreaks in cattle and humans in São Paulo, BrazilComparison of monkeypox viruses pathogenesis in mice by in vivo imagingResponse surface methodology to determine optimal cytokine responses in human peripheral blood mononuclear cells after smallpox vaccination.Evaluation of smallpox vaccines using variola neutralization.Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.Optimizing high dimensional gene expression studies for immune response following smallpox vaccination using Taqman® low density immune arraysMathematical modeling provides kinetic details of the human immune response to vaccination.Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.Development of a Genus-Specific Antigen Capture ELISA for Orthopoxviruses - Target Selection and Optimized ScreeningAnalysis of variola and vaccinia virus neutralization assays for smallpox vaccines.Evaluating anti-Orthopoxvirus antibodies in individuals from Brazilian rural areas prior to the bovine vaccinia eraAntibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.A novel, killed-virus nasal vaccinia virus vaccine.Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities.Antibody responses to vaccinia membrane proteins after smallpox vaccination.Seroprevalence of Orthopoxvirus in rural Brazil: insights into anti-OPV immunity status and its implications for emergent zoonotic OPV.Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus ChallengeSafety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assayImmune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.The smallpox vaccine induces an early neutralizing IgM response.Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.Serologic evidence of orthopoxvirus infection in buffaloes, Brazil.Dairy production practices and associated risks for bovine vaccinia exposure in cattle, Brazil.Serological Evidence of Orthopoxvirus Circulation Among Equids, Southeast Brazil.
P2860
Q21558664-B4CA9994-765F-4298-9E7E-7632A01565F5Q33492317-4E73640E-7823-4330-8185-02531277A4F5Q33714136-A1B852E2-3189-465F-A3FA-F55408CDD3C7Q33920540-54A448AF-8CF9-46BD-B011-A8538D0340BCQ33967713-0FF2D81F-CFDF-44E6-8244-8DE0A519F426Q33987410-E012E7B5-BBE6-4579-93A4-C52676AB4520Q34634341-127F0B26-D378-4E9A-A477-32E5D8DDBCC4Q34885695-B74F6D8A-FBD6-4C43-AA63-A51202A4CB07Q35557123-CFDC9CCA-6498-447E-BB0B-36F4B109E681Q35941208-89659BC2-CD16-4CA6-A9B8-F5F50614510CQ36086257-2031DA04-196B-46F5-9860-B2C6CDF1899BQ36341272-0F72357E-42D2-4873-9371-5C10E092AFF6Q36424513-F9DE7233-A246-49EA-9FC4-D62EE544643EQ36452370-C2497961-382E-4DBC-A447-83D982E2851FQ36498147-063A1DF4-A581-4D56-9E50-7430B1937FBDQ36825059-88BEBB3F-0921-4E8C-ACB7-0182A05D8FACQ36869365-B5DEE10C-7C27-4F89-9051-EF9C23A66198Q37064431-EFD2CCC2-BEA8-4DC7-A609-1B9B265DC78FQ37067250-51416418-8862-4534-9282-AB1A34745E5EQ37127399-834CE685-DF05-4054-B557-DF7B4D3A5F76Q37269295-DF44F809-1CAE-49DD-8C53-222306E9D120Q37301894-17CED67A-AE88-4529-85FE-F640CF79C0FCQ37375372-0D907C95-DE10-4AB9-9643-886036C306D3Q37456873-49560A19-9EB5-4DC2-BA55-ACA99AB2AE90Q40117821-67B6AB2E-95EB-4F93-A07A-646820DE62E1Q42573945-0584B287-A493-4293-8D61-0DB4F35C138CQ47117695-36CFB48E-637C-40D9-A58D-9DEE87EECB9DQ51783122-989A5F90-D739-48B6-AB93-D9CAFF699CD8
P2860
Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Improved assay to detect neutr ...... ted vaccinia (Dryvax) vaccine.
@ast
Improved assay to detect neutr ...... ted vaccinia (Dryvax) vaccine.
@en
type
label
Improved assay to detect neutr ...... ted vaccinia (Dryvax) vaccine.
@ast
Improved assay to detect neutr ...... ted vaccinia (Dryvax) vaccine.
@en
prefLabel
Improved assay to detect neutr ...... ted vaccinia (Dryvax) vaccine.
@ast
Improved assay to detect neutr ...... ted vaccinia (Dryvax) vaccine.
@en
P2093
P2860
P1476
Improved assay to detect neutr ...... ted vaccinia (Dryvax) vaccine.
@en
P2093
Andres Bonifacio
Frances K Newman
Mahendra Mandava
Robert B Belshe
Sharon E Frey
Tamara P Blevins
P2860
P304
P356
10.1128/JCM.41.7.3154-3157.2003
P407
P577
2003-07-01T00:00:00Z